期刊文献+

非小细胞肺癌组织中抑癌基因蛋白和血管内皮生长因子C的表达 被引量:1

Association between Maspin protein and vascular endothelial growth factor-C expression in non-small cell lung cancer
下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)组织中Maspin蛋白与血管内皮生长因子C(VEGF-C)表达及其相关性。方法NSCLC组织石蜡标本100例,正常支气管黏膜及良性病变10例,采用免疫组化技术检测组织中Maspin蛋白与VEGF-C表达,结合临床病理,探讨两者与蛋白表达水平的意义。结果NSCLC组织与正常支气管黏膜及良性病变组织比较,Maspin蛋白阳性表达率较低,分别为51.0%vs 90.0%,VEGF-C表达率较高,分别为86.0%vs40.4%(均P<0.01)。结论在NSCLC组织中Maspin蛋白低表达,其转移能力增强可能与Maspin蛋白表达下调、缺失有关,有淋巴结转移比无淋巴结转移Maspin蛋白表达阳性率低;VEGF-C的高表达与组织分化和淋巴结转移有关,分化程度高和无淋巴结转移的组织VEGF-C的表达阳性率高。 Objective To explore the association between Maspin protein and vascular endothelial growth factor- C(VEGF-C) expression in non-small cell lung cancer(NSCLC). Methods Maspin and VEGF-C proteins were detected in formalin-fixed paraffin-embedded tissue specimens from 100 cases of NSCLC tissues and 10 cases of normal lung tissues by immunohistochemical method. To analyze the level of their expression, different clinical and pathological characteristics. Results The positive rate of Maspin protein expression was lower(51.00% vs 90.00%) but the positive rate of VEGF-C expression was higher in NSCLC than normal lung tissues significantly (86.0 % vs 40.4% )(both P 0.01). Conclusion Expression of Maspin shows down regulation in NSCLC tissues. It is correlated to the malignant transfers of NSCLC tissues, expression of Maspin in NSCLC tissue with tumour node metastases is lower than that without tumour node metastases; the higher expression of VEGF-C correlates to the histodifferentiation and tumour node metastases in NSCLC tissues, the higher histodifferentiation without tumour node metastases, the expression of VEGF-C is higher.
出处 《临床荟萃》 CAS 北大核心 2008年第15期1077-1079,共3页 Clinical Focus
关键词 非小细胞肺 基因 肿瘤抑制 血管内皮生长因子 carcinoma, non-small-cell lung genes, tumor suppressor vescular endothelial growth factor C
  • 相关文献

参考文献8

二级参考文献19

  • 1姜彦多 夏书月 王继红 等.肺癌血管内皮细胞生长因子的表达与意义[J].细胞与分子免疫学杂志,1997,(1):89-89.
  • 2NEAFELD G, TESSLER S, GITAY-GOREN H, et al.Vascular endothelial growth factor and its receptors[J]. Prog Growth Fact Res,1994,5(1):89-97.
  • 3THICKETT D R,ARMSTRONG L, MILLAR A B. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions[J]. Thorax, 1999,54(8) : 707-710.
  • 4GABRILOVICH D J, CHEN H L, GIRGIS K R, et al.Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells[J].Nat Med,1996,2(10) :1096-1103.
  • 5FERARA N,SMYTH T D. The biology of vascular endothelial growth factor [J]. Endocrine Rev,1997,18(1) :4-25.
  • 6TAMURA M, OHTA Y, KAJITA T, et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in nonsmall cell lung cancer[J]. Oncology Reports, 2001,8 (5) : 1097-1102.
  • 7BANKS R E,FORBES M A,KINSEY S E, et al. Release of the angiogenic cytokine vascular endothelial growth factor(VEGF) from platelets: Significance for VEGF measurements and cancer biology[J]. Br J Cancer, 1998,77(6): 956-964.
  • 8TAKIGAWA N,SEGAWA Y,FUJIMOTO N, et al. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer [J]. Anticancer Res, 1998, 18 (2B): 1251-1254.
  • 9MATSUYAMA W, HASHIGUCHI T, MIZOGUCHI A, et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer[J ]. Chest,2000,118(4): 948-951.
  • 10KIDO Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer[J]. Kurume Medical Journal,2001,48(1) :43-47.

共引文献22

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部